Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Advanced Instruments
| Company | Advanced Instruments |
|---|---|
| Name of analyzer | GloCyte Automated Cell Counter for CSF |
| Contact | Maria Martinek |
| City, State | Norwood, MA |
| Phone | 800-225-4034 |
| Website | |
| Analyzer application | diagnostic and research use |
| Dimensions of analyzer (H × W × | 10.0 × 6.0 × 8.0 in./— |
| Country where analyzer was | U.S./U.S. |
| First year analyzer was sold in U.S./Approximate No. of units installed in U.S.* | 2016/200 |
| First year analyzer sold outside | — |
| Foreign locations where company | U.K. (installed in U.K.) |
| Human languages (other than | — |
| Analyzer list price | — |
| • Analyzer acquisition options | purchase |
| Training included with purchase/Total time for basic training per operator | — |
| • Follow-up training available | yes |
| Parameters that analyzer tests and reports | — |
| Types of testing FDA cleared or approved for analyzer | — |
| Types of body fluids FDA cleared or approved for analysis on analyzer | CSF |
| Analytical measurement range for body fluid | RBC count: 2–123 cells/µL (reportable range, 2–615, 644 cells/µL); TNC count: 3–123 cells/µL (reportable range, 3–6, 500 cells/µL) |
| Precision for body fluid | RBC count: 2.7–16.3%; TNC count: 2.5–18% |
| Accuracy for body fluid | — |
| Automated differential performed for body fluids | — |
| Tests available for research use only | — |
| Differential methods used | — |
| Analytical measurement range: • WBC count/RBC count | WBC: — (TNC: 3–6, 500 cells/µL)/RBC: 2–123 cells/µL (reportable range, 2–615, 644 cells/µL) |
| Precision: • WBC count/RBC count | — |
| Accuracy: • WBC count/RBC count | — |
| Interfering substances: • WBC/RBC | — |
| • Hemoglobin/Platelets | — |
| • Hematocrit/Reticulocytes | — |
| • Automated differential | — |
| Throughput: max. CBCs per hour/Max. CBCs with differentials per hour | — |
| • Max. No. of slides processed per hour if stainer included | — |
| FDA-cleared or -approved sample container types (besides potassium EDTA) | — |
| Min. specimen volume open mode/Closed mode/Microsample capability | 60 µL/—/no |
| Types of patient data archived/Max. No. of archived patient data accessible when analyzer online | sample type, sample appearance, sample color, accession number, result/>100, 000 results |
| Analyzer performs delta checks | no |
| Parameters for which flags may appear | control results out of range, expired reagents warning |
| Analyzer recognizes and holds test results | yes, for potential test rerun (parameters for flags to hold samples defined by vendor) |
| Scattergram display uses cell-specific color | no |
| Histogram display uses color with thresholds | no |
| LIS interface formats supported | RS232, bidirectional |
| • Middleware interface | no (connects directly to LIS) |
| • Information transferred to LIS via middleware or LIS interface | numeric results, flagged results, patient orders |
| Analyzer transmits LOINC codes for results to LIS or middleware | yes |
| Lab automation system or workcells to which analyzer has a direct interface | none |
| Barcode symbologies read on specimen tube | Codabar, Data Matrix, Code 39, Code 128 |
| • Analyzer allows barcode placement per CLSI standard Auto02-A2 | yes (also supports QR codes) |
| No. of onboard reagents required for standard specimen analysis | 2 |
| • Reagents ready to use/Reagent tracking method | yes/RFID, barcode reader |
| Onboard diagnostics for troubleshooting | yes |
| • Manufacturer can perform diagnostics via remote access | no |
| Warranty provided/Cost of annual service contract (24 h/7 d) | one-year warranty/— |
| Notes | — |